AIMS Medical Science, 2017, 4(4): 456-464. doi: 10.3934/medsci.2017.4.456.

Research article

Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study

1 Division of Medical Oncology, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy;
2 Center of Experimental Oncology and Hematology, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy;
3 Division of Medical Oncology, A.R.N.A.S. Garibaldi Nesima, Catania, Italy.
§ These Authors equally contributed to this work.

Objective: In the placebo-controlled CORRECT study, individuals with metastatic colorectal cancer (mCRC) receiving Regorafenib (RGR) achieved significant benefits in both median overall survival (OS: 6.4 months) and progression-free survival (PFS 1.9 months). Patients included in the study had previously failed all standard therapies, which must have included Fluoropyrimidines (FPDs), Oxaliplatin, Irinotecan, Bevacizumab, and Cetuximab or Panitumumab for K-RAS wild-type subjects. FPDs plus Mitomycin C (MMC) represent one of the few treatment options for mCRC patients currently eligible for RGR. We wanted to investigate the therapeutic benefit of this pharmacological association in the same clinical setting defined for RGR. Methods: We retrospectively evaluated the records of mCRC patients followed in our Institutions that would have fulfilled inclusion/exclusion criteria for the CORRECT trial and received instead the combination of FPDs and MMC. We therefore collected data from 87 patients: 61 fulfilled the criteria required for this analysis. Results: Median OS was 9.3 months (95% CI 9.0–15.4), with a median PFS of 3.3 months (95% CI 2.9–3.8). One third of the patients (29.5%) achieved disease control. No significant differences in OS and PFS were found between K-RAS WT and K-RAS mutant individuals. Likewise, Performance Status (PS) and the primary site of disease were not associated with differences in response rates. Conclusions: These results suggest the need for a prospective study assessing RGR cost-effectiveness compared to FPDs plus MMC for mCRC patients that progress after standard treatments.
  Figure/Table
  Supplementary
  Article Metrics

Keywords Colorectal Cancer; Chemotherapy; Mitomycin C; Fluorouracil; Capecitabine; Regorafenib

Citation: Federica Martorana, Paolo Vigneri, Stefano Sergio Cordio, Concetta Martines, Giuseppe Novello, Marco Maria Aiello, Roberto Bordonaro, Hèctor J. Soto Parra. Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study. AIMS Medical Science, 2017, 4(4): 456-464. doi: 10.3934/medsci.2017.4.456

References

  • 1. Ferlay J, Soerjomataram I, Dikshit R, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-386.    
  • 2. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66: 7-30.    
  • 3. Meta-analysis Group In C, Piedbois P, Rougier P, et al. (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308.    
  • 4. Kopetz S, Chang GJ, Overman MJ, et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683.    
  • 5. Waddell T, Cunningham D (2013) Evaluation of regorafenib in colorectal cancer and GIST. Lancet 381: 273-275.    
  • 6. Vigneri PG, Tirro E, Pennisi MS, et al. (2015) The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol 5: 230.
  • 7. Chong G, Dickson JL, Cunningham D, et al. (2005) Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93: 510-514.    
  • 8. Rosati G, Rossi A, Germano D, et al. (2003) Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23: 2981-2985.
  • 9. Lim DH, Park YS, Park BB, et al. (2005) Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56: 10-14.
  • 10. Kang EJ, Choi YJ, Kim JS, et al. (2010) Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. Asia Pac J Clin Oncol 6: 286-291.    
  • 11. Saif MW, Kaley K, Brennan M, et al. (2013) Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. Anticancer Res 33: 2743-2746.
  • 12. Zygulska AL, Krzemieniecki K (2015) Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C. Neoplasma 62: 793-797.    
  • 13. Dimou A, Syrigos KN, Saif MW (2010) Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin Investig Drugs 19: 723-735.    
  • 14. Ferrarotto R, Machado K, Mak MP, et al. (2012) A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48: 820-826.    
  • 15. Wilhelm SM, Dumas J, Adnane L, et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245-255.    
  • 16. Grothey A, Van Cutsem E, Sobrero A, et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381: 303-312.    
  • 17. Jang GS, Kim MJ, Ha HI, et al. (2013) Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer. Chin J Cancer Res 25: 689-694.
  • 18. Goldstein DA, Ahmad BB, Chen Q, et al. (2015) Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. J Clin Oncol 33: 3727-3732.    
  • 19. Kimura M, Usami E, Iwai M, et al. (2016) Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer. Mol Clin Oncol 5: 635-640.    
  • 20. Graziano F, Rulli E, Biagioli E, et al. (2016) Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancer. Ann Oncol 27: 747-748.    
  • 21. Mayer RJ, Van Cutsem E, Falcone A, et al. (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372: 1909-1919.    

 

Reader Comments

your name: *   your email: *  

Copyright Info: 2017, Federica Martorana, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved